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AbstrAct
Background SLE is an autoimmune condition affecting 
predominantly women. Little is known regarding Chlamydia 
trachomatis infection in women with SLE, which may drive 
autoimmunity and contribute to obstetrical and vascular 
complications.
Methods This single-centre, case–control study set 
primary endpoint in the comparative seropositivity rate 
to C. trachomatis major outer membrane protein (MOMP) 
and chlamydial heat-shock protein-60 (cHSP60) in 
age-matched subjects. The secondary endpoints were 
obstetrical outcomes, cardiovascular events and results 
from screening procedures for cervical cancer.
Results Eighty-four women with SLE and 50 age-matched 
controls were included. Seropositivity to C. trachomatis 
did not differ significantly between groups (10% of cases 
positive for anti-MOMP vs 12% of controls; 43% of cases 
positive for anti-cHSP60 vs 32% of controls). Women 
with SLE were more often of non-Caucasian ethnicity and 
had lower educational level. They relied less frequently 
on oral contraception and resorted more frequently to 
elective pregnancy termination. Pre-eclampsia and ectopic 
pregnancy occurred only in SLE. Women with SLE also 
experienced more cardiovascular events. In SLE, antibodies 
to cHSP60 were associated with a history of pericarditis 
and abnormal screening tests for cervical cancer. Antibody 
titres to C. trachomatis were not associated with disease 
activity or SLE treatment, nor were there associations with 
other gynaecological, obstetrical or vascular outcomes.
Conclusion Prevalence of antibodies to C. trachomatis 
was not increased in women with SLE. No significant 
association was found between these antibodies and 
obstetrical or cardiovascular complications.
IntRoduCtIon
SLE is a chronic inflammatory disorder 
characterised by multiorgan damage and 
the generation of a vast array of autoanti-
bodies. SLE mainly affects women of repro-
ductive age. The strong gender predilection 
suggests that sexual hormones are involved 
in disease pathogenesis and progression, but 
gender-specific genetic and environmental 
differences may also be implicated.1–3 It 
has been postulated that the autoimmune 
processes underlying SLE may be triggered by 
certain pathogens in genetically susceptible 
individuals. One prime candidate is Epstein-
Barr virus,4 although results regarding its 
implication in SLE are conflicting. Informa-
tion on the role of sexually transmitted path-
ogens in SLE is limited. Chlamydia trachomatis 
is a common sexually transmitted obliga-
tory intracellular bacteria. Infection with 
C. trachomatis usually results in urethritis in 
men and cervicitis in women. In women, C. 
trachomatis infection is frequently clinically 
silent, and some develop endometritis, salpin-
gitis or pelvic inflammatory disease, which 
may lead to ectopic pregnancy, miscarriage 
and tubal infertility.5 6 About 10% of indi-
viduals in the general population have anti-
bodies to C. trachomatis.7–9 In Switzerland, C. 
trachomatis seroprevalence and C. trachomatis 
prevalence assessed by quantitative PCRs in 
urogenital samples are similar to those in 
other European countries, being respectively 
10%6 and 5%.10 This prevalence of chlamydia 
DNA was slightly lower (about 2%) in young 
asymptomatic Swiss men.11 C. trachomatis 
infection has been linked to reactive arthritis, 
an autoimmune entity mostly diagnosed 
in male subjects.12 C. trachomatis produces 
microbial heat-shock proteins (HSP), such as 
chlamydial HSP60 (cHSP60), a stress mole-
cule with a high degree of homology between 
species.13–15 Thus, infection with C. trachomatis 
may trigger an immune response with gener-
ation of anti-cHSP60 antibodies, which could 
cross-react with human HSP60. Human 
HSP60 is expressed on endothelial cells. 
HSP60-reactive T cells as well as anti-HSP60 
antibodies have been linked to atheroscle-
rosis.16 In SLE, the presence of antibodies to 
human HSP60 was associated with increased 
arterial vascular events, when associated 
with antiphospholipid antibodies.17 Acceler-
ated atherosclerosis is of particular concern 
in SLE. Based on the role of C. trachomatis 
in autoimmunity and vascular damage, we 
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hypothesised that infection with C. trachomatis may be 
more prevalent in women with SLE. A study in patients 
with reactive arthritis had indeed found an increased 
seroprevalence of antibodies to C. trachomatis in controls 
with SLE compared with healthy subjects, although this 
difference was not statistically significant.18 Serology 
for C. trachomatis, both against chlamydial major outer 
membrane protein (MOMP) and cHSP60, has a limited 
sensitivity for acute infection.19 It is however the most reli-
able tool to assess past infection. A positive serology tends 
to be associated with more severe infections (eg, pelvic 
inflammatory disease).20 Our main objective was to inves-
tigate the prevalence of both antibodies to C. trachomatis 
MOMP and to the less specific cHSP60 in female patients 
with SLE, compared with age-matched controls. We also 
investigated pregnancy outcomes and cardiovascular 
events in both groups, as these are of particular concern 
in women with SLE21 22 and because of their potential link 
with C. trachomatis infection.
Methods
We conducted a case–control study between 15 December 
2014 and 13 April 2015. All participants were recruited 
sequentially. Cases were female adults with SLE attending 
the outpatient clinic of Lausanne University Hospital. 
Controls were women attending the same outpatient 
clinic for allergy tests. Cases and controls were matched 
per decade of age, in order to obtain the same age distri-
bution between groups. All participants provided a blood 
sample and completed a questionnaire on reproductive 
health outcomes. Additional information was gathered 
from hospital files and gynaecologists’ records, when 
available. Inclusion criteria for cases were definite SLE 
according to the revised American College of Rheuma-
tology (ACR)23 and/or the Systemic Lupus International 
Collaborating Clinics criteria.24 Cases were recruited into 
the Swiss SLE Cohort Study and assessed according to a 
detailed questionnaire on SLE features. Exclusion criteria 
for controls were evident autoimmunity or non-allergic 
inflammatory conditions. Exclusion criteria for both 
groups were active neoplasia or infection.
The questionnaire assessed demographical, gynae-
co-obstetrical and cardiovascular variables. Data included 
age at menarche, age at first intercourse, means of contra-
ception, number of sexual partners, number of pregnan-
cies and pregnancy outcomes, occurrence of menopause 
and frequency of gynaecological follow-up. Additional 
data were extracted from the hospital medical file and 
obtained from gynaecologists in private practice through 
a telephone interview, and included details on screening 
procedures for cervical cancer (Pap test according to 
Bethesda classification, and where available colposcopy 
and biopsy results), on pregnancy outcomes (sponta-
neous fetal losses, extrauterine pregnancies, preterm 
births before the 32nd week of gestation, pre-eclampsia 
defined as hypertension >140/90 mm Hg and protein-
uria >300 mg/24 hours since the 20th week of gestation, 
and eclampsia defined as status epilepticus in a context 
of pre-eclampsia) and on thromboembolic events (signifi-
cant ischaemic stroke translating in an acute neurological 
symptomatology, acute ST-elevation myocardial infarction 
(STEMI) or non-STEMI, unprovoked acute deep venous 
thrombosis and clinically significant acute pulmonary 
embolism; all cardiovascular events were documented by 
radiological findings or coronarography).
Serology against C. trachomatis was performed in all 
participants using ELISA, with IgG to C. trachomatis MOMP 
(Chlamydia trachomatis-IgG-pELISA; ref 497-TMB; Medac, 
Wedel, Germany) and HSP60 (cHSP60-IgG-pELISA; ref 
435; Medac). The MOMP Medac assay is described as one 
of the most sensitive and specific commercially available, 
noticeably because it does not cross-react with C. pneumo-
niae MOMP and HSP60.25 Cross-reactivity of C. trachomatis 
anti-HSP60 with human anti-HSP60 is unknown and was 
not assessed in the present study. Intra-assay variability was 
3.4% (coefficient of variation for MOMP assay) and 4.3% 
(coefficient of variation for cHSP60 assay), as reported by 
the manufacturer.
Relative luminescence (defined according to the manu-
facturer’s instruction) of 1.1 or more was considered as a 
positive result, and a relative luminescence of 0.9 or less 
was considered negative. Before analyses, we decided to 
consider borderline antibody titres 0.9–1.1 as negative.
Clinical information regarding lupus disease duration, 
activity according to Safety of Estrogens in Lupus Erythe-
matosus National Assessment-Systemic Lupus Erythema-
tosus Disease Activity Index (SELENA-SLEDAI) score,26 
and past and present treatment was were documented for 
SLE cases.
Distribution comparisons (Student’s t-test) and bivar-
iate analyses (χ2 and Fisher’s methods according to the 
number of cases) were used to assess differences between 
groups (group matching). P values under 0.05 were 
considered statistically significant. Missing values were 
excluded from analyses. Given the explorative nature of 
the study, we did not apply post-hoc procedures to correct 
for multiple comparisons.27 Analyses were conducted 
using SPSS V.22 for Windows.
Results
Baseline characteristics
Eighty-four women with SLE and 50 age-matched controls 
were included (figure 1). The mean age at inclusion was 
44 years. Demographics in women with SLE and controls 
are compared in table 1. Women with SLE significantly 
differed from controls with regard to ethnic background, 
with 58% being Caucasians, compared with 88% in the 
control group. Educational level also tended to be lower 
in the SLE group, with 57% having attended college, 
professional school or university, compared with 72% in 
the control group.
There was no difference in age at menarche, age at 
first intercourse or number of sexual partners between 
groups. The use of oral contraceptives was significantly 
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Figure 1 Study flow chart. Cases with SLE are on the left and age-matched controls are on the right. Controls excluded after 
screening had systemic autoimmunity (n=8), autoimmune endocrinopathy (n=6), chronic spontaneous urticaria (n=4), active 
neoplasia (n=3) and other unclear medical conditions (n=3; pulmonary transplant for cystic fibrosis, non-allergic asthma and 
pruritus of unknown origin).
lower in SLE and reported by 66% of women, compared 
with 82% of controls. On the other hand, only women 
with SLE had received medroxyprogesterone acetate 
injections. Other means of contraception did not differ 
between groups. Forty-one (49%) women with SLE 
declared having reached menopause, compared with 
18 (36%) of controls (NS). In the SLE group, 79% had 
seen a gynaecologist in the 2 years preceding inclusion, 
compared with 90% of controls (NS).
Primary outcomes
Antibody titres to C. trachomatis MOMP and cHSP60 are 
shown in figure 2. As expected, there was a moderate 
correlation between MOMP and cHSP60 antibody titres 
(Spearman’s r=0.29). The proportion of seropositives 
did not differ between groups, with 8 (10%) cases posi-
tive to MOMP compared with 6 (12%) controls, and 36 
(43%) cases positive to cHSP60, compared with 16 (32%) 
controls (p=0.77 and p=0.27, respectively). The rate of 
seropositivity to C. trachomatis antigens did not correlate 
with age, socioeconomic background, ethnicity, early 
sexual activity, type of contraception used and number 
of sexual partners reported. Also, seropositivity to MOMP 
or cHSP60 was not associated with historical results for C. 
trachomatis vaginal swab testing, although only performed 
in 25% of patients and exceptionally positive. Finally, 
seropositivity was not associated with self-reported C. 
trachomatis infection (data not shown).
secondary outcomes
Pregnancy rates did not differ between groups (71% 
of patients in the SLE group and 72% of controls). 
Obstetrical outcomes are shown in table 2. There was 
no difference in the number of live births and spon-
taneous fetal losses. Extrauterine pregnancies were 
reported in three patients with SLE and did not occur 
in controls. Elective abortions were more frequent in 
SLE and reported by 48% of women with pregnancies, 
compared with 22% of controls. Pre-eclampsia, eclampsia 
and hemolysis, elevated liver enzymes, low platelet count 
(HELLP) syndrome occurred only in the SLE group and 
were reported in 10% of patients with pregnancies. No 
association was observed between elective abortion or 
any pregnancy complication (fetal losses, prematurity in 
subjects with SLE or in controls; extrauterine pregnancy, 
pre-eclampsia/eclampsia in subjects with SLE) and either 
anti-MOMP or anti-cHSP60 antibodies (data not shown).
Cardiovascular events are listed in table 3. Taken 
together, arterial and venous vascular events had 
occurred in 29% of women with SLE, compared with 4% 
of controls (p=0.001). This difference was mainly due to 
venous thromboembolism, which had only occurred in 
patients with SLE. Stroke and myocardial infarction were 
more frequent in SLE, although not statistically signifi-
cant. Patients with arterial vascular events were older than 
those without, although this was not statistically signifi-
cant (median age 51 years compared with 43; p=0.055). 
Within the SLE group, vascular events occurred in 15 of 
41 (37%) of those without a history of positive testing 
for antiphospholipid antibodies, compared with 7 of 42 
(16%) of those negative (p=0.047). This association was 
only seen with arterial vascular events, which occurred 
in 10 patients positive to antiphospholipid antibodies, 
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Table 1 Baseline characteristics of 84 women with SLE and 50 age-matched controls
Cases Controls P values
Age, mean±SD, years 44±13 44±14 0.97
Ethnic origin, n (%) 0.001
  Caucasian 49 (58) 44 (88)
  African 14 (17) 1 (2)
  Asian 11 (13) 1 (2)
  Other 10 (12) 4 (8)
Higher education*, n (%) 48 (57) 36 (72) 0.099
Age at menarche, n (%), years 0.58
  9–11 12 (14) 11 (22)
  12–13 44 (52) 22 (44)
  14–15 22 (26) 12 (24)
  ≥16 6 (7) 5 (10)
Having used contraceptive methods, n (%) 77 (92) 46 (92) 1.00
  Oral contraception 55 (66) 41 (82) 0.048
  Contraceptive implant 2 (2) 3 (6) 0.36
  Medroxyprogesterone acetate injection 8 (10) 0 (0) 0.025
  Diaphragm 4 (5) 5 (10) 0.29
  Condom 34 (41) 27 (54) 0.15
  Intrauterine device 23 (27) 13 (26) 1.00
Age at first sexual intercourse, n (%), years 0.36
  <16 8 (10) 8 (16)
  16–20 46 (55) 31 (62)
  >20 26 (31) 10 (20)
  Never had sexual intercourse 4 (5) 1 (2)
Number of sexual partners, n (%) 0.34
  0–1 26 (31) 12 (24)
  2–4 33 (39) 17 (34)
  ≥5 25 (30) 21 (42)
Menopause at inclusion, n (%) 41 (49) 18 (36) 0.16
Last gynaecological visit <2 years ago, n (%) 66 (79) 45 (90) 0.10
Having a gynaecologist in private practice, n (%) 50/83 (60) 36/49 (74) 0.14
*Defined as continued education after obligatory school.
compared with 1 patient negative to antiphospholipid 
antibodies (p=0.003). No association was found between 
cardiovascular events (stroke, myocardial infarction, 
pulmonary embolism, deep venous thrombosis) and 
either anti-MOMP or anti-cHSP60 antibodies, in patients 
with SLE or in controls (data not shown). The results 
from screening procedures for cervical cancer were avail-
able in 80% of participants, with abnormal tests reported 
in 30% of screened subjects with SLE and 27% of controls 
(NS). Findings were atypical squamous cells of underter-
mined significance (ASC-US) in 8 patients, low-grade 
squamous intraepithelial lesions/cervical intraepithe-
lial neoplasia-grade 1 (LSIS/CIN-1) in 15, high-grade 
squamous intraepithelial lesions/cervical intraepithelial 
neoplasia-grade 2-3 (HSIL/CIN2-3) in 7, and 1 had an 
unspecified abnormal result.
Association of serological results within the sle group
Disease characteristics and treatment modalities of 
patients with SLE are shown in table 4. Subjects with SLE 
had a median disease duration of 8 years and fulfilled a 
median number of 6 ACR classification criteria for SLE. 
Most patients with lupus suffered from photosensitive 
rash, arthritis and haematological disorder. Forty-three 
(52%) had lupus nephritis, with four patients under 
permanent dialysis or one having received a kidney graft. 
The median SELENA-SLEDAI score was 5, consistent with 
moderately active SLE in most patients. Seventy-one per 
cent of patients were taking antimalarials, and approxi-
mately half were taking low-dose corticosteroids and/
or immunosuppressants during the month preceding 
assessment. The most frequently used immunosuppres-
sant was mycophenolate mofetil (45% of subjects under 
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Figure 2 Antibody (Ab) titres to Chlamydia trachomatis 
major outer membrane protein (A) and chlamydial heat-shock 
protein-60 (cHSP60) (B) in 84 women with SLE (cases) and 50 
age-matched controls.
Table 2 Pregnancy outcomes in 60 women with SLE and 36 age-matched controls
Pregnancy outcomes
Subjects, n (%) Cases Controls P values
History of elective abortion 29 (48) 8 (22) 0.017
History of fetal loss 23 (38) 11 (31) 0.51
  ≥3 fetal losses 3/23 (8) 1/11 (9) 1.00
History of ectopic pregnancy 3/53 (6) 0 (0) 0.28
Live births 52 (87) 31 (86) 1.00
  Number of live births, median (IQR) 2 (1–3) 2 (2–3) 0.77
  History of pre-eclampsia or eclampsia, n (%) 5/48 (10) 0/29 (0) 0.15
  History of preterm birth, n (%) 5/48 (10) 1/29 (3) 0.40
Table 3 Cardiovascular events in 84 women with SLE and 
50 age-matched controls
History of cardiovascular 
event,
Subjects, n (%) Cases Controls P values
Arterial events* 11 (13) 2 (4) 0.13
  Stroke 9 (11) 1 (2) 0.09
  Myocardial infarction 4 (5) 1 (2) 0.65
Venous event† 15 (18) 0 (0) 0.001
  Deep vein thrombosis 10 (12) 0 (0) 0.013
  Pulmonary embolism 7 (8) 0 (0) 0.045
Arterial and/or venous events 22 (26) 2 (4) 0.002
*2 patients with SLE suffered from both stroke and myocardial 
infarction.
†4 patients with SLE had both venous and arterial vascular 
events.
immunosuppression). Twelve patients received biologics 
at the time of assessment (rituximab in 6, belimumab in 4, 
abatacept in 1 and tocilizumab in 1 patient). Seventy-five 
per cent of patients had been under immunosuppressant 
therapy at least once during the course of the disease.
Patient characteristics with regard to cHSP60 serology 
are shown in table 4. Those positive for cHSP60 anti-
bodies had more often a history of pericarditis (42% in 
cHSP60-positive, compared with 19% in cHSP60-nega-
tive; p=0.03). As previously reported, there was no signif-
icant association between cHSP60 seropositivity and 
vascular events (17% of arterial events in cHSP60-posi-
tive, compared with 10% in cHSP60-negative). There was 
no significant association of antibodies to cHSP60 with 
other disease features, including global disease activity 
and treatment modalities. No associations between anti-
MOMP and clinical characteristics were found (data not 
shown).
There was a significant association between anti-
cHSP60 and abnormal Pap smear results in patients 
with SLE (50% with abnormal results in patients with 
anti-cHSP60 antibodies, compared with 16% in patients 
without these; p=0.004). No such difference was found in 
controls, nor was seropositivity to MOMP associated with 
cervical dysplasia in either group.
dIsCussIon
In this single-centre study, prevalence of antibodies to 
chlamydial MOMP and cHSP60 did not significantly differ 
between women with SLE and age-matched controls. 
The seroprevalence of 10% specific antibodies to C. 
trachomatis we found is similar to the reported frequency 
of C. trachomatis exposure in the general Swiss6 and Euro-
pean female population.8 9 Only a minority of subjects 
had undergone vaginal swab tests for C. trachomatis, and 
serology did not correlate with these findings nor with 
self-reported C. trachomatis infection. When comparing 
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negative (n=48) P values
Age at assessment, mean±SD (range), years 44.2±13.4 (22–81) 41.9±11.6 45.9±14.5 0.18
Disease duration, median (IQR), years 8 (3–15) 9.5 (5–15) 7 (2–14) 0.31
Number of ACR classification criteria fulfilled, median (IQR)* 6 (5–7) 6 (5–8) 6 (5–7) 0.98
  Nasopharyngeal ulcers, n (%) 26/83 (31) 15 (42) 11 (23) 0.097
  Pericarditis, n (%) 24/83 (29) 15 (42) 9 (19) 0.03
  Antiphospholipid antibodies, n (%) 41/83 (49) 22 (61) 19 (40) 0.077
Disease activity at assessment
  SELENA-SLEDAI, median (IQR) 5 (2–10) 6 (2–9) 4.5 (2–12) 0.68
Treatment
  Systemic corticosteroids during the past month, n (%) 40/77 (52) 20 (59) 20 (47) 0.36
   High-dose steroids (prednisone >10 mg/day), n (%) 3/40 (8) 1 (5) 2 (10) 1.00
  Antimalarial therapy during the past month, n (%) 55/77 (71) 26 (77) 29 (67) 0.45
  Immunosuppressant during the past month, n (%)† 42/77 (55) 18 (53) 24 (56) 0.82
  Immunosuppressant ever, n (%) 58 (75) 27 (79) 31 (66) 0.22
Damage
  Any thrombotic or ischaemic event, n (%) 22 (26) 11 (31) 11 (23) 0.46
  Dialysis or renal transplantation, n (%) 5 (6) 4 (11) 1 (2) 0.16
cHSP60=chlamydial heat-shock-protein-6; SD=SD deviation; IQR=IQR range;
*No significant association found for photosensitivity, malar rash, discoid rash, arthritis, pleuritic, renal disorder, haematological disorder, 
seizures, psychosis, ANA, antidouble-stranded DNA antibodies and anti-Smith antibodies.
†Mycophenolate mofetil (n=19), azathioprine (n=9), rituximab (n=6), belimumab (n=4), methotrexate (n=4), calcineurin inhibitor (n=2), 
abatacept (n=1) and tocilizumab (n=1), without significant differences between groups.
ACR, American College of Rheumatology; cHSP60, chlamydial heat-shock protein-6; SELENA-SLEDAI, Safety of Estrogens in Lupus 
Erythematosus - National Assessment-Systemic Lupus Erythematosus Disease Activity Index.
known risk factors for sexually transmitted diseases such 
as early onset of sexual activity and increased number of 
sexual partners, we did not find a significant association 
with serology results nor differences between SLE and 
controls. Aside from these classic risk factors, contracep-
tive methods differed between SLE and controls, with 
lower use of combined oral contraceptive in women with 
SLE and higher use of medroxyprogesterone acetate 
injections (likely secondary to SLE diagnosis). A higher 
rate of elective abortion in patients with SLE may reflect 
a lower socioeconomic status and reduced access to effec-
tive contraception. Cases and controls differed in terms 
of ethnicity, with more patients with SLE being of African 
or Asian descent. In addition, fewer patients with SLE 
had achieved higher professional education compared 
with controls. This may reflect the increased prevalence 
of SLE in ethnic minorities and lower socioeconomic 
status.28 29 Only women with SLE did experience pre-ec-
lampsia, which is a well-known risk in this population.30 
Ectopic pregnancies were reported by three patients, all 
in the SLE group. However, the rate of live births was the 
same in SLE and controls. No association between preg-
nancy outcomes and seropositivity to C. trachomatis was 
found. These results contrast with previous observations 
suggesting a relationship between miscarriage and C. 
trachomatis infection.6 31 Cardiovascular events were signif-
icantly more frequent in women with SLE compared with 
age-matched controls. Indeed, accelerated atheroscle-
rosis and thrombotic events linked to antiphospholipid 
antibodies are feared complications of SLE. Most of our 
patients with lupus had long-standing disease and half 
had severe disease with renal involvement. While vascular 
events were more frequent in patients with SLE with 
antiphospholipid antibodies, we did not find an associa-
tion with antibodies to MOMP or cHSP60.
Very few studies have assessed exposure to C. trachomatis 
in SLE. One study on reactive arthritis had included 30 
patients with SLE, which displayed a threefold increase 
in seroprevalence against C. trachomatis compared with 
healthy controls.18 A study assessed C. trachomatis by 
vaginal swab test and did not find an increased preva-
lence in patients with SLE.32 Another study investigated 
the potential relationship between coronary calcifica-
tions as a marker of atherosclerotic burden and PCR 
for C. pneumoniae and C. trachomatis in the peripheral 
blood monocytes of patients with SLE, without finding 
a clear association.33 Most patients with SLE included 
in our study had disease features beyond articular and 
cutaneous involvement. A majority had received immu-
nosuppressive treatment. Most patients had long-lasting 
and well-controlled disease at assessment. Antibodies to 
cHSP60 were slightly more prevalent in SLE and were 
associated with a history of lupus pericarditis. Others have 
found that a history of lupus pericarditis might define a 
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subgroup of patients with more aggressive disease.34 We 
did not find an association of anti-cHSP60 antibodies with 
other features of severe SLE, although more patients in 
this group had end-stage renal disease. A possible expla-
nation for an association of antibodies to cHSP60 with 
pericarditis could be the tendency of Chlamydia species to 
induce serositis, as in the Fitz-Hugh-Curtis syndrome or 
in some reported cases of pericarditis and myocarditis.35 
However, no association between anti-MOMP antibodies 
and pericarditis was found. Another finding with regard to 
anti-cHSP60 antibodies was their association with abnor-
malities on screening tests for cervical cancer. One could 
argue that human papilloma virus (HPV) usually under-
lying cervical dysplasia might be transmitted together 
with C. trachomatis, as coinfection frequently occurs and 
facilitates oncogenesis,36 a finding reflected by the pres-
ence of antibodies to cHSP60. On the other hand, no 
association between cervical dysplasia and antibodies to 
C. trachomatis MOMP was found that would support this 
hypothesis. More studies relying on PCR techniques 
are needed to assess the role of HPV and C. trachomatis 
coinfection in SLE. Upregulation of HSP60 expression 
has been reported in women with cervical cancer.37 One 
could argue that upregulation of HSP60 by dysplastic 
cells in the cervix might trigger cross-reactive antibodies, 
given the high grade of homology with cHSP60. We did 
however not assess whether antibodies to cHSP60 cross-
react with human HSP60, which was beyond the scope of 
this study. It is finally possible that due to the multiplicity of 
statistical tests performed, the association of anti-cHSP60 
antibodies with pericarditis and cervical dysplasia in the 
lupus subset is due to chance. We did not find an increase 
in cervical dysplasia in patients with SLE compared with 
controls. However, larger population-based studies have 
shown that cervical dysplasia is an important issue in SLE 
and that the risk increases in women with long-standing 
immunosuppression.38
Although this study has limitations, such as its cross-sec-
tional design and the limited sample size, its strengths lie 
in the detailed assessment of participants and the use of 
two reliable and complementary serological tests for C. 
trachomatis. We considered the possibility that infection 
with C. trachomatis might drive autoimmunity in SLE, but 
the results show an equal distribution of antibodies to C. 
trachomatis in age-matched controls, which speaks against 
a prominent role of this pathogen in lupus and associ-
ated damage. Studies relying on PCR techniques to detect 
ongoing infection with C. trachomatis in patients with early 
lupus are needed to confirm these results. Our study 
results also support known issues in women with SLE, 
which are increased risk of adverse obstetrical outcomes 
and cardiovascular events.
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